Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | ACP1 | P24666 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21605932 | 1.00 | KDM1A (0.44) | KDM1ACHEK1ACP1BRD4ATAD2 | |
| SCHEMBL1413601 | 0.90 | BRD3 (0.43) | KDM1ACHEK1BRD4ATAD2CDK4 | |
| SCHEMBL530604 | 0.84 | CHEK1 (0.44) | KDM1ACHEK1ACP1 | |
| SCHEMBL8178820 | 0.84 | KMT2A (0.49) | KDM1ACHEK1ACP1BRD4ATAD2 | |
| SCHEMBL13769159 | 0.81 | KDM1A (0.47) | KDM1ACHEK1BRD4ATAD2SYK | |
| SCHEMBL3053522 | 0.80 | SCN9A (0.47) | KDM1ACHEK1 | |
| SCHEMBL22414312 | 0.80 | RAB9A (0.44) | — | |
| SCHEMBL1565671 | 0.80 | RAB9A (0.44) | — | |
| SCHEMBL20240266 | 0.77 | LTA4H (0.48) | CHEK1 | |
| SCHEMBL25330831 | 0.77 | JAK2 (0.45) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2019243526-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | KDM1A 1144/4885CHEK1 289/4885ACP1 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.